Theravance Biopharma (NASDAQ:TBPH) SVP Rhonda Farnum Sells 13,314 Shares of Stock

Posted by Brian Himes on Sep 18th, 2026

Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Free Report) SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $17.03, for a total transaction of $226,737.42. Following the completion of the transaction, the senior vice president directly owned 213,476 shares in the company, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Theravance Biopharma Stock Up 0.1%

NASDAQ:TBPH opened at $17.04 on Friday. The firm has a market capitalization of $884.72 million, a P/E ratio of 16.87 and a beta of 0.25. The company has a fifty day moving average of $16.96 and a 200 day moving average of $16.40. Theravance Biopharma, Inc. has a 52 week low of $13.08 and a 52 week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH – Get Free Report) last released its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to analysts’ expectations of $22.49 million. Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. As a group, analysts anticipate that Theravance Biopharma, Inc. will post 1.56 EPS for the current year.

Analysts Set New Price Targets

TBPH has been the subject of a number of research analyst reports. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a research note on Monday, August 17th. Zacks Research lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. BTIG Research cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 29th. JonesTrading lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research note on Monday, June 29th. Finally, HC Wainwright cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and boosted their price target for the company from $15.00 to $17.00 in a research report on Tuesday, July 7th. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat, Theravance Biopharma presently has an average rating of “Hold” and an average target price of $19.40.

Read Our Latest Stock Analysis on TBPH

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently modified their holdings of TBPH. Dimensional Fund Advisors LP increased its stake in shares of Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 124,658 shares in the last quarter. Pacer Advisors Inc. bought a new position in shares of Theravance Biopharma during the fourth quarter valued at $6,342,000. Bank of America Corp DE raised its position in shares of Theravance Biopharma by 78.2% in the 1st quarter. Bank of America Corp DE now owns 189,155 shares of the biopharmaceutical company’s stock worth $3,070,000 after purchasing an additional 82,978 shares during the last quarter. Wedge Capital Management L L P NC bought a new stake in Theravance Biopharma during the 2nd quarter valued at about $2,190,000. Finally, Renaissance Technologies LLC purchased a new position in Theravance Biopharma in the first quarter worth about $2,076,000. Institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

(Get Free Report)

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.